Adial Pharmaceuticals, Inc.
ADIL
$6.44
-$0.21-3.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 87.31% | 0.83% | 2.46% | -4.50% | -5.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.42% | -13.48% | -5.86% | -3.36% | 14.13% |
| Operating Income | -38.42% | 13.48% | 5.86% | 3.36% | -14.13% |
| Income Before Tax | -584.09% | 13.18% | 39.56% | 38.21% | 30.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -584.09% | 13.18% | 39.56% | 38.21% | 30.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -584.09% | 13.18% | 39.56% | 38.29% | 30.97% |
| EBIT | -38.42% | 13.48% | 5.86% | 3.36% | -14.13% |
| EBITDA | -38.42% | 13.48% | 5.86% | 3.36% | -14.13% |
| EPS Basic | 45.82% | 75.58% | 80.48% | 76.65% | 74.39% |
| Normalized Basic EPS | 83.09% | 75.92% | 79.82% | 76.04% | 73.70% |
| EPS Diluted | 45.82% | 75.58% | 80.48% | 76.65% | 74.39% |
| Normalized Diluted EPS | 83.09% | 75.92% | 79.82% | 76.04% | 73.70% |
| Average Basic Shares Outstanding | 577.66% | 310.92% | 243.96% | 198.87% | 176.17% |
| Average Diluted Shares Outstanding | 577.66% | 310.92% | 243.96% | 198.87% | 176.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |